Gemcitabine elaidate hydrochloride

SKU: orb1308275

Description

Gemcitabine elaidate hydrochloride (CP-4126) is a lipophilic, orally bioavailable prodrug of gemcitabine. It is activated intracellularly by esterases to release gemcitabine for phosphorylation, exhibiting schedule-dependent antitumor activity in preclinical in vivo and in vitro cancer models.

Research Area

Cell Biology, Molecular Biology

Key Properties

• CAS Number: 2918768-08-6
• MW: 564.11
• Purity: 99.60% (May vary between batches)
• Formula: C₂₇H₄₄ClF₂N₃O₅
• SMILES: O[C@@H](C(F)(F)[C@H](N1C(N=C(C=C1)N)=O)O2)[C@H]2COC(CCCCCCC/C=C/CCCCCCCC)=O.Cl
• Target: Autophagy,Others,Apoptosis,Nucleoside Antimetabolite/Analog
• Solubility: DMSO:5.65 mg/mL (10.02 mM)

Bioactivity

• In Vivo:
  Gemcitabine elaidate hydrochloride, administered intraperitoneally (i.p.) at doses ranging from 25 to 120 mg/kg every three days for five doses, has demonstrated efficacy in inhibiting the growth of solid tumor xenografts in non-small cell lung cancer (EKVX), non-classifiable sarcoma (MHMX), fibrous histiocytoma (TAX II-1), malignant melanoma (THX), prostate cancer (CRL-1435), and pancreatic cancer (PANC-1). Furthermore, when given orally (p.o.) at 10-20 mg/kg following the same schedule, it exhibits acceptable toxicity levels and significant antitumor activity against colon cancer xenograft in Co6044 bearing mice. A once-daily oral dose for five days shows favorable toxicity and antitumor profiles; however, a 15 mg/kg dose proves highly toxic in the same colon cancer model. Female BALB/c nude (nu/nu) mice, aged 5-8 weeks and weighing 20-27 g, served as the animal model for these experiments, bearing various tumors including EKVX, H-146, MHMX, TAX II-1, OHS, THX, MA-11, CRL-1435, PANC-1, and MiaPaCa-2. The treatment notably inhibited tumor growth in specific models, achieving T/C values of 7%, 1%, 30%, 7%, 9%, and 12% for EKVX, MHMX, TAX II-1, THX, CRL-1435, and PANC-1, respectively.
• In Vitro:
  Gemcitabine elaidate hydrochloride, at concentrations ranging from 0.2 nM to 1 mM over 72 hours, effectively inhibits the growth of both gemcitabine-sensitive and drug-resistant cells, demonstrating IC50 values varying from 0.0015 to 91 μM across different cell lines (L1210/L5, L4A6, BCLO, Bara-C, C26-A, C26-G, A2780, AG6000, THX, LOX, MOLT4, and MOLT4/C8, respectively). Additionally, exposure to gemcitabine elaidate (0.5 nM to 1 μM; 72 h) in A549 and WiDR cells leads to a significant increase in S phase accumulation and triggers dose-dependent cell death. Detailed cell cycle analysis of A549 and WiDR cells treated with various concentrations (0.0005 to 1.0 μM) for 72 hours confirmed the induction of G2/M and S phase accumulation.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

CP 4126 Hydrochloride, CP4126 Hydrochloride, CP-4126 Hydrochloride, CP-4126 hydrochloride, CO101 Hydrochloride, CO-101 Hydrochloride, CO-101 hydrochloride, CO 101 Hydrochloride, Gemcitabine elaidate hydrochloride, Gemcitabine elaidate hydrochloride(210829-30-4(free base)), Gemcitabine 5'-elaidate Hydrochloride, Gemcitabine 5'-elaidate hydrochloride, Gemcitabine elaidate Hydrochloride

Compound Identifiers

PubChem CID

155977587